Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 47 | 1.140 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2023 | 2 | 0.870 |
Why?
|
| Chromosomes, Human | 1 | 2021 | 14 | 0.790 |
Why?
|
| Clone Cells | 1 | 2021 | 67 | 0.790 |
Why?
|
| Microarray Analysis | 1 | 2021 | 63 | 0.780 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 44 | 0.770 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 475 | 0.680 |
Why?
|
| HIV Infections | 1 | 2023 | 791 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 446 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 468 | 0.340 |
Why?
|
| Prognosis | 3 | 2023 | 2093 | 0.320 |
Why?
|
| Cell- and Tissue-Based Therapy | 3 | 2022 | 35 | 0.310 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 135 | 0.300 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 132 | 0.290 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 17 | 0.220 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 70 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2023 | 7277 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 116 | 0.200 |
Why?
|
| Benzodiazepines | 1 | 2022 | 130 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 151 | 0.190 |
Why?
|
| Genomic Instability | 1 | 2021 | 41 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 231 | 0.190 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 36 | 0.190 |
Why?
|
| Interleukin-15 | 1 | 2021 | 66 | 0.180 |
Why?
|
| Humans | 11 | 2023 | 68618 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 511 | 0.180 |
Why?
|
| Salvage Therapy | 1 | 2019 | 82 | 0.170 |
Why?
|
| Disease Progression | 1 | 2021 | 1038 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 245 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 117 | 0.080 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2010 | 142 | 0.080 |
Why?
|
| Middle Aged | 3 | 2021 | 21147 | 0.070 |
Why?
|
| Aged | 2 | 2021 | 14862 | 0.070 |
Why?
|
| Male | 3 | 2021 | 37321 | 0.060 |
Why?
|
| Female | 3 | 2021 | 38074 | 0.060 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2023 | 7 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2023 | 25 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 144 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 96 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 127 | 0.050 |
Why?
|
| Rituximab | 1 | 2021 | 61 | 0.050 |
Why?
|
| Standard of Care | 1 | 2019 | 22 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 376 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 145 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 216 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 266 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 536 | 0.040 |
Why?
|
| Mutation | 1 | 2023 | 1213 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 332 | 0.040 |
Why?
|
| Young Adult | 2 | 2019 | 5717 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3259 | 0.030 |
Why?
|
| Missouri | 1 | 2010 | 44 | 0.020 |
Why?
|
| Adult | 2 | 2019 | 21403 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 867 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 1426 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 1619 | 0.020 |
Why?
|
| Obesity | 1 | 2010 | 1076 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 4848 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 8912 | 0.010 |
Why?
|